Lv41
438 积分 2025-09-13 加入
比咖啡更提神的是打翻咖啡。
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
20天前
已完结
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
20天前
已完结
KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)
21天前
已完结
Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial
23天前
已完结
KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC
23天前
已完结
New promises and challenges in the treatment of advanced non-small-cell lung cancer
24天前
已完结
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer
1个月前
已完结
Updated treatment recommendations for systemic treatment: from the ESMO non-oncogene addicted-metastatic NSCLC Living Guideline†
1个月前
已完结
Pan-cancer analysis to character the clinicopathological and genomic features of KRAS-mutated patients in China
1个月前
已完结
Landscape of Concomitant Driver Alterations in Classical EGFR-Mutated Non–Small Cell Lung Cancer
1个月前
已完结
皖公网安备34019202002308
